BDNF raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-11-27. Anything still debated is marked as such rather than presented as settled.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
| Property | Value | Notes |
|---|---|---|
| Common route | Intranasal | Also injected in some animal work |
| Solubility class | Freely soluble in water | Solid form is hygroscopic |
| Typical storage | About -20 degrees Celsius | Keep desiccated and dark |
| Purity method | Reverse-phase HPLC | Reported as area percent |
| Confirmatory method | Mass spectrometry | Verifies expected molecular mass |
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
Organ on a chip applications: For example organoids can be used to model diseases with cells derived from patients or they can be used to investigate the development of different tissues (for example the nervous system) in humans and other animals. Some of these areas are further elaborated in the sections below:
Xi's position as the apparent successor to become the paramount leader was threatened with the rapid rise of Bo Xilai, the party secretary of Chongqing at the time. Bo was expected to join the PSC after the 18th Party Congress, with most expecting that he would try to eventually maneuver himself into replacing Xi. Bo's policies in Chongqing inspired imitations throughout China and received praise from Xi himself during Xi's visit to Chongqing in 2010. Records of praises from Xi were later erased after he became paramount leader. Bo's downfall would come with the Wang Lijun incident, which opened the door for Xi to come to power without challengers. On 18 October 2010, at the fifth plenary session of the 17th Central Committee, Xi was elected to be a vice chairman of the CCP Central Military Commission, followed by his appointment as vice chairman of the state CMC on 28 October by the Standing Committee of the National People's Congress. A few months before his ascendancy to the party leadership, Xi disappeared from official media coverage and cancelled meetings with foreign officials for several weeks beginning on 1 September 2012, causing rumors. He then reappeared on 15 September. On 15 November 2012, immediately after the 18th Party National Congress, Xi was elected by the first plenary session the 18th Central Committee to the posts of Party general secretary and chairman of the Party CMC. This made him both the CCP leader and, informally, China's paramount leader. The following day Xi led the new line-up of the PSC onto the stage in their first public appearance.
== Awards and honours == In 1987, he was awarded the Royal Society of Chemistry medal for Analytical Separations and in 1991, was awarded the Martin Medal by the Chromatographic Society. In 1993 he received the Gold Medal of the Society of Analytical Chemistry. The International Mass Spectrometry Society awarded him the J.J.Thomson Medal in 1997, and in 1999 he received the A.J.Evans Medal from Cardiff University. He was a past Chairman of the BMSS, served on the SERC Chemistry Committee as Chairman of the Instrumentation Panel and also on NERC, MRC and AFRC panels. He was a former Joint Editor-in-Chief of Biomedical and Environmental Mass Spectrometry.
The RTS,S vaccine was endorsed by the World Health Organization in October 2021 for broad use in children, making it the first malaria vaccine to receive this recommendation. As of April 2022, 1 million children in Ghana, Kenya and Malawi have received at least one shot of the vaccine, with more doses being provided as the vaccine production ramps up. RTS,S reduces hospital admissions from severe malaria by around 30%.
Sources: en.wikipedia.org
Population coverage: some countries have large surveillance networks that cover most of their population, while others use a smaller subset of hospitals and laboratories to generate data intended to be representative of the broader population. Sampling: EARS-Net data are only collected for invasive isolates (from blood or cerebrospinal fluid). These samples may not be representative of the members of this species that can colonize and infect humans, so resistance rates for other infections, such as urinary tract infections may vary. In some settings, laboratory microbiology work may only be performed in cases where initial antibiotic treatment has failed, leading to an overestimation of resistance rates. Laboratory routines and capacity: interpretation of minimum inhibitory concentration may vary across laboratories and countries, depending on current practice. Recommendations around converting minimum inhibitory concentration to resistance status also change over time, making comparison of resistance rates over time challenging.
The primary structure of a biological polymer to a large extent determines the three-dimensional shape (tertiary structure). Protein sequence can be used to predict local features, such as segments of secondary structure, or trans-membrane regions. However, the complexity of protein folding currently prohibits predicting the tertiary structure of a protein from its sequence alone. Knowing the structure of a similar homologous sequence (for example a member of the same protein family) allows highly accurate prediction of the tertiary structure by homology modeling. If the full-length protein sequence is available, it is possible to estimate its general biophysical properties, such as its isoelectric point.
== References == Anderson, G.B., (1999). "Epidemiological features of chronic low back pain". The Lancet (1) 354 Langevin, H.M., Bouffard, N.A., Badger, G.J., Churchill, D.L., Howe, A.K., (2006). "Subcutaneous tissue fibroblasts cytoskeletal remodeling induced by acupuncture: evidence for a mechanotransduction-based mechanism". J Cell Physiol (3) 207 Langevin, H.M., Churchill, D.L., Cipolla, M.J., (2001). "Mechanical signalling through connective tissue: A mechanism for the therapeutic effect of acupuncture". FASEB J (1) 15
== Non-human infections == Streptococcus agalactiae was historically studied as a disease of cattle that harmed milk production, leading to its name "agalactiae" which means "absence of milk". Strains of bovine and human bacteria are generally interchangeable, with evidence of transmission from animals to humans and vice versa.
=== Strabismus === Ophthalmologists specializing in eye muscle disorders (strabismus) had developed the method of EMG-guided injection (using the electromyogram, the electrical signal from an activated muscle, to guide injection) of local anesthetics as a diagnostic technique for evaluating an individual muscle's contribution to an eye movement. Because strabismus surgery frequently needed repeating, a search was undertaken for non-surgical, injection treatments using various anesthetics, alcohols, enzymes, enzyme blockers, and snake neurotoxins. Finally, inspired by Daniel B. Drachman's work with chicks at Johns Hopkins, Alan B. Scott and colleagues injected botulinum toxin into monkey extraocular muscles. The result was remarkable; a few picograms induced paralysis that was confined to the target muscle, long in duration, and without side effects. After working out techniques for freeze-drying, buffering with albumin, and assuring sterility, potency, and safety, Scott applied to the FDA for investigational drug use, and began manufacturing botulinum type A neurotoxin in his San Francisco lab. He injected the first strabismus patients in 1977, reported its clinical utility in 1980, and had soon trained hundreds of ophthalmologists in EMG-guided injection of the drug he named Oculinum ("eye aligner"). In 1986, Oculinum Inc, Scott's micromanufacturer and distributor of botulinum toxin, was unable to obtain product liability insurance, and could no longer supply the drug. As supplies became exhausted, people who had come to rely on periodic injections became desperate.
Sources: en.wikipedia.org
Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.
Reported human trials are few, brief and originate mainly from one country. They describe effects on anxiety-related measures, but sample sizes are small and reporting is limited. The results are widely regarded as preliminary rather than confirmed.
Reverse-phase liquid chromatography is used to assess purity and separation of related impurities. Mass spectrometry confirms that the observed molecular mass matches the expected peptide. A certificate of analysis from the supplier is the usual document of record.
Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.